StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.23−0.46 (-5.29%)

Close on Nov 18, 2026Market cap $239.70MP/E –Yield –

Enanta Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Enanta Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$62.38M. For fiscal 2026 it was -$62.38M. The highest annual figure on record is $124.15M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2026Sep 30, 2026-$62.38M–
FY2025Sep 30, 2025-$85.35M–
FY2024Sep 30, 2024-$121.69M–
FY2023Sep 30, 2023-$137.21M–
FY2022Sep 30, 2022-$123.84M–
FY2021Sep 30, 2021-$109.57M–
FY2020Sep 30, 2020-$41.64M-213.3%
FY2019Sep 30, 2019$36.74M-58.4%
FY2018Sep 30, 2018$88.33M+258.9%
FY2017Sep 30, 2017$24.61M-20.2%
FY2016Sep 30, 2016$30.84M-75.2%
FY2015Sep 30, 2015$124.15M+553.9%
FY2014Sep 30, 2014$18.99M+110.3%
FY2013Sep 30, 2013$9.03M-57.6%
FY2012Sep 30, 2012$21.29M-15.9%
FY2011Sep 30, 2011$25.30M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ3 2026Sep 30, 2026-$22.04M–
Q3 FY2026CQ2 2026Jun 30, 2026-$17.24M–
Q2 FY2026CQ1 2026Mar 31, 2026-$11.85M–
Q1 FY2026CQ4 2025Dec 31, 2025-$11.25M–
Q4 FY2025CQ3 2025Sep 30, 2025-$18.39M–
Q1 FY2025CQ4 2024Dec 31, 2024-$23.54M–
Q4 FY2024CQ3 2024Sep 30, 2024-$29.85M–
Q3 FY2024CQ2 2024Jun 30, 2024-$24.19M–
Q2 FY2024CQ1 2024Mar 31, 2024-$32.77M–
Q1 FY2024CQ4 2023Dec 31, 2023-$34.89M–
Q4 FY2023CQ3 2023Sep 30, 2023-$31.03M–
Q3 FY2023CQ2 2023Jun 30, 2023-$36.71M–
Q2 FY2023CQ1 2023Mar 31, 2023-$39.45M–
Q1 FY2023CQ4 2022Dec 31, 2022-$30.01M–
Q4 FY2022CQ3 2022Sep 30, 2022-$27.05M–
Q3 FY2022CQ2 2022Jun 30, 2022-$32.54M–
Q2 FY2022CQ1 2022Mar 31, 2022-$33.85M–
Q1 FY2022CQ4 2021Dec 31, 2021-$30.41M–
Q4 FY2021CQ3 2021Sep 30, 2021-$33.73M–
Q3 FY2021CQ2 2021Jun 30, 2021-$33.85M–
Q2 FY2021CQ1 2021Mar 31, 2021-$29.70M–
Q1 FY2021CQ4 2020Dec 31, 2020-$12.30M-195.6%
Q4 FY2020CQ3 2020Sep 30, 2020-$19.78M-407.6%
Q3 FY2020CQ2 2020Jun 30, 2020-$22.85M-708.6%
Q2 FY2020CQ1 2020Mar 31, 2020-$11.88M–
Q1 FY2020CQ4 2019Dec 31, 2019$12.87M-53.8%
Q4 FY2019CQ3 2019Sep 30, 2019$6.43M-81.3%
Q3 FY2019CQ2 2019Jun 30, 2019$3.76M-83.4%
Q2 FY2019CQ1 2019Mar 31, 2019-$1.30M-107.7%
Q1 FY2019CQ4 2018Dec 31, 2018$27.86M+93.8%
Q4 FY2018CQ3 2018Sep 30, 2018$34.45M-36.5%
Q3 FY2018CQ2 2018Jun 30, 2018$22.64M–
Q2 FY2018CQ1 2018Mar 31, 2018$16.86M–
Q1 FY2018CQ4 2017Dec 31, 2017$14.38M–
Q4 FY2017CQ3 2017Sep 30, 2017$54.30M–
Q3 FY2017CQ2 2017Jun 30, 2017-$13.13M–
Q2 FY2017CQ1 2017Mar 31, 2017-$9.51M–
Q1 FY2017CQ4 2016Dec 31, 2016-$7.05M–
Q4 FY2016CQ3 2016Sep 30, 2016-$3.10M–

More Enanta Pharmaceuticals figures

See a number that looks wrong?